with a solution of the enteric coating ingredients in ethanol (containing 10% acetone). The coating on each capsule is about 17 mg. The capsules meet the enteric coating test described herein and do not disintegrate within 2 hours in artificial gastric juices (pH 1, HCl). The compositions are stable, e.g for 2 years at room temperature,

If desired larger capsules containing 534.3 mg MFA mono sodium salt may be made in analogous manner, reducing the amount of lactose. These are well tolerated in clinical trials.

EXAMPLE 2

Capsules of size 1 are made up as in Example 1. A solution for enteric coating was made up as follows:

Hydroxypropyl methyl cellulose phthalate (HP50)	270 g
Triacetin	30 g
Acetone	900 g
Ethanol	1800 g

600 g of this enteric coating solution was used for 1 kg of capsules (ca. 2400). The amount of coating applied to each capsule was about 25 mg giving a film thickness of 5–6 mg/cm^2.

What is claimed is:

1. A pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to prevent release of mycophenolate in the stomach.

2. The composition of claim **1** wherein the composition has an enteric coating and said enteric coating comprises cellulose acetate phthalate and trimellitate, or methacrylic acid copolymers containing at least 40% methacrylic acid, or hydroxypropyl methylcellulose phthalate.

3. The composition of claim **2** wherein said coating comprises methacrylic acid copolymers containing at least 40% methacrylic acid.

4. The composition of claim **2** wherein said composition is in a tablet form.

5. The composition of claim **4**, wherein said tablet has a hardness between 10 and 70 N.

6. The composition of claim **2** wherein said composition is in a granule or pellet form.

7. The composition of claim **6** wherein said granule or pellet is contained in a capsule.

8. The composition of claim **1** wherein said salt is a mono-sodium salt.

9. The composition of claim **8** wherein said salt is in crystalline form.

10. The composition of claim **1** wherein said composition comprises from about 50 mg to 1.5 g of a pharmaceutically acceptable mycophenolate salt.

11. A pharmaceutical composition comprising a mycophenolate mono-sodium salt, the composition being adapted to prevent release mycophenolate in the stomach, wherein said composition has an enteric coating and said enteric coating comprises cellulose acetate phthalate and trimellitate, or methacrylic acid copolymers containing at least 40% methacrylic acid, or hydroxypropyl methylcellulose phthalate.

12. The composition of claim **11** wherein said mono-sodium salt is in crystalline form.

13. The composition of claim **11** herein said composition is in a tablet form and said tablet form has a hardness between 10 and 70 N.

14. The composition of claim **11** wherein said composition comprises from about 50 mg to 1.5 of a pharmaceutically acceptable mycophenolate salt.

* * * * *